[Therapy of recurrent herpes simplex and its surveillance by MIF determination: with levamisole, BCG, urushiol and herpes antigen vaccine (author's transl)].
Thirty patients with recurrent herpes simplex and 6 controls were included in our study. Before initiation of treatment, during therapy with Levamisole, BCG, poison ivy and herpes antigen vaccine and, thereafter, MIF-determinations were performed. The latter test proved to be a useful parameter in evaluating the sensitivity against herpes infection, (and subsequent recurrent manifestations), and effect of therapy. Treatment with Levamisole, BCG and herpes antigen vaccine was successful. MIF-inhibition values paralleled the therapeutic effect in the Levamisole- and herpes antigen vaccine treated group, not however, in the BCG-treated patients
D000956:Antigens, Viral; D001500:BCG Vaccine / Q000627:therapeutic use; D002464:Cell Migration Inhibition; D005500:Follow-Up Studies; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy; D007978:Levamisole / Q000627:therapeutic use; D008263:Macrophage Migration-Inhibitory Factors / Q000627:therapeutic use; D008264:Macrophages; D010936:Plant Extracts / Q000627:therapeutic use; D010947:Plants, Toxic; D012008:Recurrence; D012251:Toxicodendron
D000956:Antigens, Viral; D001500:BCG Vaccine; D008263:Macrophage Migration-Inhibitory Factors; D010936:Plant Extracts; D007978:Levamisole
MIF in der Therapiekontrolle von Herpes simplex recidivans: Bhandlung mit Levamisole, BCG, Urushiol und Herpes Antigen Vaccine